Support for Your Viral-Based Vaccines and Therapeutics
With foundational expertise and comprehensive capabilities in viral drug development and manufacturing, Emergent can help navigate your manufacturing program from clinical to commercial scale.
Our team has worked with a wide range of viruses, including adenovirus, rVSV (Vesiculo-Stomatitis Virus), Modified Vaccinia Ankara (MVA), and Baclovirus. Our viral facilities offer contained BSL2 drug substance manufacturing. Over the years, we’ve worked with a number of cell lines, including CHO, PER.C6, HEK293, Vero, and our proprietary A549 cell line. Emergent regularly invests in the latest technology and high-level expertise to ensure we have what’s needed to support your emerging viral platforms.
With the ability to scale up new products and efficiently transfer existing ones in our cGMP production lines, our operations-focused model can help you accelerate your clinical timelines.